

## Capital raising of \$3.1 million to accelerate growth

**Sydney, Australia – 2 September 2015: Medibio Limited (MEB or the Company)** is pleased to announce that it has received firm commitments to raise approximately \$3.1 million by the placement of 7,730,087 ordinary shares at a price of \$0.40. The placement will be conducted using the company's existing placement capacity under ASX Listing Rule 7.1. The placement was strongly supported by domestic institutions, Foster Stockbroking has acted as sole Lead Manager for the capital raising.

The company intends to use the the placement proceeds to fast track the commercialisation of its Circadian Heart Rate (CHR) technology which offers the first objective test to assist in the diagnosis of depression, other mental health disorders, and the assessment of stress. A number of initiatives will be moved forward with the aim to start them this calendar year rather than their previously programmed starts in 2016 or 2017. The initiatives to be fast tracked include:

- Build of the full commercial version of the Corporate Stress Assessment product
- Independent validation of the Corporate Stress Assessment product to allow Medibio to go to market with external validation from a leading academic institution
- Testing program on the key wearable devices and a wearables currently under development
- Pivotal Studies on Post Traumatic Stress Disorder
- Pivotal Study to demonstrate the clinical validity of CHR to determine depression treatment efficacy
- Pivotal Studies on Anxiety Disorder and potentially mixed Depression and Anxiety

<b>Further Information:</b>		Website: <a href="http://www.medibio.com.au">www.medibio.com.au</a>
<b>Medibio Shareholder Enquiries to:</b> Kris Knauer CEO and Director Medibio Limited <a href="mailto:kris.knauer@medibio.com.au">kris.knauer@medibio.com.au</a> T: +61 (0)411 885979	<b>Medibio Media Enquiries to:</b> Peter Taylor NWR Communications <a href="mailto:Peter@nwrcommunications.com.au">Peter@nwrcommunications.com.au</a> T: +61 (0)412 036 231	

### ABOUT MEDIBIO LIMITED

Medibio (ASX: MEB), is a medical technology company developing a new objective test to assist in the diagnosis of depression, other mental health disorders, and chronic stress. This test utilizes circadian heart rate variability. The technology is based on research conducted over 15 years and studies are currently being undertaken by Johns Hopkins University School of Medicine and the University of New South Wales to validate its clinical utility. The technology consists of a heart monitor that sends ECG recordings wirelessly to the cloud where proprietary algorithms analyse and deliver a quantifiable measure which can be used by a clinician to assist in diagnosis. The technology has the potential to be the first FDA approved objective, evidence based approach to the diagnosis of depression and other mental health disorders. Medibio is not just a traditional medical device company with revenue dependent upon regulatory approval. It has the only new and credible method for the diagnosis of stress and mental wellbeing which can be easily translated to the workplace stress/wellbeing market, wearable technology, and App market. Located in Sydney, NSW, Medibio is listed on the Australian Stock Exchange.